Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
rna interference
6
×
alnylam pharmaceuticals
boston
boston top stories
clinical trials
drugs
biotech
national top stories
new york blog main
san francisco blog main
aminolevulinic acid
barry greene
dan ollendorf
fda
givosiran
new york top stories
patisiran
regeneron pharmaceuticals
san francisco top stories
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alexion pharmaceuticals
alirocumab
alnylam pharmaceutials
amgen
amy schulman
andreas klein
anna greka
arrowhead pharmaceuticals
boehringer ingelheim
boston university
car-t
caron jacobson
cigall kadoch
What
rna
6
×
alnylam
interference
ago
drug
medicine
medicines
pharmaceuticals
rnai
data
fda
long
market
new
second
seek
speedy
abandoning
approval
approve
aren’t
awaits
baggage
based
biological
car
cholesterol
cleared
companies
crossed
cuts
cutting
deal
decades
decision
development
dicerna
discovered
edge
evidence
Language
Current search:
rna
×
" rna interference "
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”